Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleo… Read more
Chenguang Biotech Group (300138) - Net Assets
Latest net assets as of September 2025: CN¥3.39 Billion CNY
Based on the latest financial reports, Chenguang Biotech Group (300138) has net assets worth CN¥3.39 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.96 Billion) and total liabilities (CN¥4.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.39 Billion |
| % of Total Assets | 42.55% |
| Annual Growth Rate | 22.39% |
| 5-Year Change | 53.17% |
| 10-Year Change | 121.05% |
| Growth Volatility | 79.08 |
Chenguang Biotech Group - Net Assets Trend (2007–2024)
This chart illustrates how Chenguang Biotech Group's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chenguang Biotech Group (2007–2024)
The table below shows the annual net assets of Chenguang Biotech Group from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion | -10.69% |
| 2023-12-31 | CN¥3.53 Billion | +9.90% |
| 2022-12-31 | CN¥3.21 Billion | +15.47% |
| 2021-12-31 | CN¥2.78 Billion | +35.15% |
| 2020-12-31 | CN¥2.06 Billion | +18.29% |
| 2019-12-31 | CN¥1.74 Billion | +0.05% |
| 2018-12-31 | CN¥1.74 Billion | +7.16% |
| 2017-12-31 | CN¥1.62 Billion | +6.49% |
| 2016-12-31 | CN¥1.52 Billion | +6.85% |
| 2015-12-31 | CN¥1.43 Billion | +41.51% |
| 2014-12-31 | CN¥1.01 Billion | +1.83% |
| 2013-12-31 | CN¥990.39 Million | -0.75% |
| 2012-12-31 | CN¥997.86 Million | +3.01% |
| 2011-12-31 | CN¥968.71 Million | +3.82% |
| 2010-12-31 | CN¥933.05 Million | +342.89% |
| 2009-12-31 | CN¥210.67 Million | +42.41% |
| 2008-12-31 | CN¥147.93 Million | +45.46% |
| 2007-12-31 | CN¥101.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chenguang Biotech Group's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5020.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.89 Billion | 60.85% |
| Common Stock | CN¥483.10 Million | 15.54% |
| Other Comprehensive Income | CN¥147.46 Million | 4.74% |
| Other Components | CN¥586.86 Million | 18.87% |
| Total Equity | CN¥3.11 Billion | 100.00% |
Chenguang Biotech Group Competitors by Market Cap
The table below lists competitors of Chenguang Biotech Group ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XiAn Tian He Defense Technology Co Ltd
SHE:300397
|
$630.65 Million |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
$630.67 Million |
|
Schrödinger, Inc.
F:43Z
|
$631.00 Million |
|
Guizhou Broadcasting&TV Info
SHG:600996
|
$631.31 Million |
|
Zhongnongfa Seed Industry Group Co Ltd
SHG:600313
|
$630.39 Million |
|
NewtekOne, Inc. 8.50% Fixed Rate Senior Notes due 2031
NASDAQ:NEWTO
|
$630.37 Million |
|
Antar Chile
SN:ANTARCHILE
|
$630.30 Million |
|
Xencor Inc
NASDAQ:XNCR
|
$630.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chenguang Biotech Group's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,470,467,781 to 3,109,489,222, a change of -360,978,559 (-10.4%).
- Net income of 94,049,622 contributed positively to equity growth.
- Dividend payments of 174,054,908 reduced retained earnings.
- Share repurchases of 396,528,570 reduced equity.
- Other comprehensive income increased equity by 147,460,084.
- Other factors decreased equity by 31,904,787.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥94.05 Million | +3.02% |
| Dividends Paid | CN¥174.05 Million | -5.6% |
| Share Repurchases | CN¥396.53 Million | -12.75% |
| Other Comprehensive Income | CN¥147.46 Million | +4.74% |
| Other Changes | CN¥-31.90 Million | -1.03% |
| Total Change | CN¥- | -10.40% |
Book Value vs Market Value Analysis
This analysis compares Chenguang Biotech Group's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 36.67x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.38 | CN¥13.85 | x |
| 2008-12-31 | CN¥0.54 | CN¥13.85 | x |
| 2009-12-31 | CN¥0.74 | CN¥13.85 | x |
| 2010-12-31 | CN¥2.73 | CN¥13.85 | x |
| 2011-12-31 | CN¥2.26 | CN¥13.85 | x |
| 2012-12-31 | CN¥2.36 | CN¥13.85 | x |
| 2013-12-31 | CN¥2.34 | CN¥13.85 | x |
| 2014-12-31 | CN¥2.38 | CN¥13.85 | x |
| 2015-12-31 | CN¥3.35 | CN¥13.85 | x |
| 2016-12-31 | CN¥2.94 | CN¥13.85 | x |
| 2017-12-31 | CN¥3.18 | CN¥13.85 | x |
| 2018-12-31 | CN¥3.40 | CN¥13.85 | x |
| 2019-12-31 | CN¥3.40 | CN¥13.85 | x |
| 2020-12-31 | CN¥4.07 | CN¥13.85 | x |
| 2021-12-31 | CN¥5.27 | CN¥13.85 | x |
| 2022-12-31 | CN¥5.94 | CN¥13.85 | x |
| 2023-12-31 | CN¥6.52 | CN¥13.85 | x |
| 2024-12-31 | CN¥6.01 | CN¥13.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chenguang Biotech Group utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.34%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 2.90x
- Recent ROE (3.02%) is below the historical average (10.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.17% | 7.67% | 0.81x | 2.11x | CN¥2.81 Million |
| 2008 | 30.34% | 12.05% | 0.83x | 3.04x | CN¥25.81 Million |
| 2009 | 25.92% | 11.78% | 1.03x | 2.14x | CN¥29.95 Million |
| 2010 | 7.02% | 10.88% | 0.51x | 1.27x | CN¥-27.00 Million |
| 2011 | 7.86% | 7.00% | 0.96x | 1.17x | CN¥-20.48 Million |
| 2012 | 5.92% | 6.19% | 0.66x | 1.45x | CN¥-40.59 Million |
| 2013 | 1.06% | 0.88% | 0.73x | 1.65x | CN¥-88.24 Million |
| 2014 | 2.22% | 1.85% | 0.80x | 1.50x | CN¥-78.34 Million |
| 2015 | 4.86% | 5.43% | 0.64x | 1.41x | CN¥-72.79 Million |
| 2016 | 6.15% | 4.32% | 0.86x | 1.66x | CN¥-57.83 Million |
| 2017 | 8.79% | 5.15% | 0.96x | 1.77x | CN¥-19.67 Million |
| 2018 | 8.33% | 4.74% | 0.91x | 1.92x | CN¥-29.13 Million |
| 2019 | 11.07% | 5.93% | 0.72x | 2.58x | CN¥18.76 Million |
| 2020 | 12.97% | 6.84% | 0.84x | 2.25x | CN¥61.33 Million |
| 2021 | 12.62% | 7.21% | 0.82x | 2.14x | CN¥72.97 Million |
| 2022 | 13.71% | 6.89% | 0.91x | 2.19x | CN¥117.55 Million |
| 2023 | 13.82% | 6.98% | 0.80x | 2.46x | CN¥132.68 Million |
| 2024 | 3.02% | 1.34% | 0.78x | 2.90x | CN¥-216.90 Million |
Industry Comparison
This section compares Chenguang Biotech Group's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $1,314,559,364
- Average return on equity (ROE) among peers: 7.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chenguang Biotech Group (300138) | CN¥3.39 Billion | 13.17% | 1.35x | $630.55 Million |
| ShenZhen Kondarl Group Co Ltd (000048) | $493.88 Million | 5.67% | 1.45x | $677.04 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $473.86 Million | 3.40% | 0.49x | $192.35 Million |
| Hefei Fengle Seed Co Ltd (000713) | $541.01 Million | 5.38% | 1.28x | $460.52 Million |
| Luoniushan Co Ltd (000735) | $1.57 Billion | 5.18% | 0.35x | $939.65 Million |
| New Hope Liuhe Co Ltd (000876) | $4.62 Billion | 8.84% | 0.83x | $3.80 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $903.81 Million | 2.44% | 0.22x | $1.92 Billion |
| Dongrui Food Group Co Ltd (001201) | $326.81 Million | 2.47% | 0.90x | $262.05 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $555.07 Million | 18.79% | 0.29x | $164.61 Million |
| Boen Group Co. Ltd. Cl A (001366) | $521.42 Million | 14.80% | 0.42x | $88.79 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $3.14 Billion | 3.25% | 0.20x | $542.58 Million |